Enfortumab Vedotin with Radiation for Locally Advanced Bladder Cancer
This study is looking at whether combining enfortumab vedotin (a drug given through an IV) with radiation therapy can help control advanced bladder cancer. Researchers want to see how safe this combination is and if it helps people live longer without their cancer getting worse. You might be able to join if you are 18 or older, have a confirmed diagnosis of advanced urothelial carcinoma (a type of bladder cancer), and meet other health criteria. The study aims to enroll 41 participants. The main goal is to understand the safety and side effects of this treatment combination over about one year. The current status of this study is unclear.
- Study design
- This study is an interventional study with a planned enrollment of 41 participants. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events (side effects) will be measured throughout study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Comron Hassanzadeh, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.0